Adjuvant high dose rate brachytherapy (Ir-192) in the management of keloids which have recurred after surgical excision and external radiation.
We describe our experience with adjuvant high dose rate brachytherapy (Ir-192) (HDRB) in patients, who failed surgery and post-operative external radiation therapy. The salvage treatment consisted of excision of the keloid and wound closure followed by HDRB (15 Gy in three fractions given on three consecutive business days beginning the day of surgery). At the time of last follow up, 88% (15/17) of the keloids were without any evidence of recurrence.
Garg
Madhur K
MK
Department of Radiation Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.
Weiss
Paul
P
Sharma
Anand K
AK
Gorla
Giridhar R
GR
Jaggernauth
Wainwright
W
Yaparpalvi
Ravindra
R
Delrowe
John
J
Beitler
Jonathan J
JJ
D000293:Adolescent; D000328:Adult; D001918:Brachytherapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007627:Keloid / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D013514:Surgical Procedures, Operative / Q000379:methods; D017211:Treatment Failure; D016896:Treatment Outcome